MME and heart failure: This may be mediated by microvascular ischemia and an up‐regulated feedback loop of the renin‐angiotensin‐aldosterone system.8 By simultaneously blocking the renin‐angiotensin‐aldosterone system and augmenting natriuretic peptides through neprilysin inhibition,29 the ARNI sacubitril/valsartan promotes vasodilatation, natriuresis and inhibition of fibrosis and hypertrophy.30, 31 Thus, sacubitril/valsartan has already emerges as an innovative and promising therapeutic approach in heart failure with reduced ejection fraction.10